Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > REGULATORY
REGULATORY
- Gov’t Releases Some Documents Related to Draft Statement on Iressa Lawsuits
March 13, 2012
- MHLW Announces Requirements for “Clinical Research Core Hospitals”
March 12, 2012
- Study Group to Discuss Whether “ABC” Screening Should Be Included in Gastric Cancer Screening: Parliamentary Secretary Fujita
March 9, 2012
- DPJ’s PAL Subcommittee to Begin Compiling Recommendations in Mid-March; Timing of Bill Unclear
March 7, 2012
- Aricept to Receive 16.7-16.8% Reduction, Lyrica 25% in Re-Pricing Due to Market Expansion
March 6, 2012
- 702 Products Including DPP-4 Inhibitors to Be Eligible for New Drug Premium in April
March 5, 2012
- Private-Sector Members of Strategy Council Call for Early Establishment of Drug Discovery Support Organization
March 5, 2012
- Cancer Policy Promotion Council Submits New 5-Year Plan to Health Minister Komiyama
March 5, 2012
- Revised Ordinance Banning “Dispensing Point” Services Announced in Official Gazette
March 5, 2012
- 11 APIs/28 Products to Receive Premiums for New Pediatric, Orphan Indications
March 5, 2012
- PAFSC’s 2nd Committee on Drugs Recommends Approval for Pfizer Japan’s ALK Inhibitor Xalkori
March 1, 2012
- MHLW Study Group Approves Outline of “Post-5-Year Plan” for Promoting Clinical Trials
March 1, 2012
- PAFSC’s 2nd Committee on Drugs Recommends Orphan Drug Designation for 4 Products
February 29, 2012
- MHLW Conducts Hearing on Distribution Improvement with Drug Manufacturers
February 28, 2012
- Ikoma City Introduces Pharmacy Certification System to Promote Use of Generics
February 28, 2012
- Non-partisan Study Group Holds Hearings on Problem of Essential But Unprofitable Drugs
February 28, 2012
- Next 5-Year Strategy Calls for Boost to Japanese“Rising Sun”Seed Development
February 27, 2012
- PAFSC’s First Committee on Drugs Recommends Approval for Eli Lilly’s Once-Weekly GLP-1 Receptor Agonist
February 27, 2012
- National, Rosai Hospitals Hold 1st Meeting Aimed at Joint Purchasing in July
February 27, 2012
- Welfare Offices to Dispatch “Advisors” to Visit Welfare Recipients and Encourage Generic Drug Use
February 27, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…